Experiences of Migraine and Erenumab Treatment in Japan: Qualitative Interviews with Clinical Trial Participants

Carla Dias-Barbosa; Hisaka Igarashi; Ashley Duenas; Asha Hareendran; Shigekazu Kitamura; Shigeya Tanaka; Naoko Sanno; Hikaru Doi; Tsutomu Nagamitsu; Yoshihisa Tatsuoka; Yasuhiko Matsumori; Miki Hasebe; Takao Takeshima

doi:10.1007/s40271-026-00813-6

April 16, 2026PatientOpen Access

Experiences of Migraine and Erenumab Treatment in Japan: Qualitative Interviews with Clinical Trial Participants

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to explore the experiences of individuals undergoing erenumab treatment for migraines.
Conducted qualitative interviews with clinical trial participants
Analyzed participants' experiences and perceptions of erenumab treatment
Identified common themes in treatment experiences
Patients reported varying levels of effectiveness and side effects
Gained insights into patient perspectives on migraine management

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Qualitative interviews reveal treatment experiences with erenumab in migraine participants, suggesting improved understanding of patient perspectives.

Abstract

Clinicaltrials.gov NCT03812224. Registered January 23, 2019.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dias-Barbosa et al. (2026) studied this question.

synapsesocial.com/papers/69e4713b010ef96374d8dd62 https://doi.org/10.1007/s40271-026-00813-6

View Full Paper

Ask AI

Bookmark

Share

Experiences of Migraine and Erenumab Treatment in Japan: Qualitative Interviews with Clinical Trial Participants

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Experiences of Migraine and Erenumab Treatment in Japan: Qualitative Interviews with Clinical Trial Participants

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading